Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 4 × Neoplasms × Paclitaxel × Clear all

Phase

Phase 1 56 Phase 2 31 Phase 3 19 Phase 1/2 16 Phase NA 3 Phase 4 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Breast Neoplasms 7 Carcinoma, Non-Small-Cell Lung 3 Stomach Neoplasms 1 Squamous Cell Carcinoma of Head and Neck 1 Parkinson Disease 4, Autosomal Dominant Lewy Body 1 Ovarian Neoplasms 1 Neoplasms 1 Lung Neoplasms 1 Esophageal Squamous Cell Carcinoma 1 Esophageal Neoplasms 1 Carcinoma, Ovarian Epithelial 1 Cancer Therapy-related Cardiovascular Toxicity 1 Breast Neoplasm Female 1

Interventions

Dexamethasone 6 Oxycodone 5 Propofol 4 Epoetin Alfa 4 Zoledronic Acid 3 Sevoflurane 3 Palonosetron 3 Everolimus 3 Cholecalciferol 3 Aspirin 3 peginterferon alfa-2a 2 edoxaban 2 apixaban 2 apatinib 2 Vitamin B 12 2 Vancomycin 2 Tobacco Use Cessation Devices 2 Tablets 2 Surgical Procedures, Operative 2 Saline Solution 2 Rivaroxaban 2 Ondansetron 2 Octreotide 2 Naloxone 2 Morphine 2 Metoclopramide 2 Meropenem 2 Lidocaine 2 Lenograstim 2 Ipilimumab 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00606515 2009-02-10

LPS-PK-H

Shandong Luye Pharmaceutical Co., Ltd.

Phase 4 Completed

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡